Guardant Health, Inc.
GH
$19.10
$0.221.17%
| Weiss Ratings | GH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | GH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | GH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.77 | |||
| Price History | GH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.71% | |||
| 30-Day Total Return | -9.25% | |||
| 60-Day Total Return | -23.99% | |||
| 90-Day Total Return | -40.87% | |||
| Year to Date Total Return | -37.12% | |||
| 1-Year Total Return | -20.39% | |||
| 2-Year Total Return | -74.76% | |||
| 3-Year Total Return | -89.94% | |||
| 5-Year Total Return | -75.27% | |||
| 52-Week High % Change | -58.21% | |||
| 52-Week Low % Change | 8.54% | |||
| Price | GH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $41.06 | |||
| 52-Week Low Price | $15.81 | |||
| 52-Week Low Price (Date) | Apr 19, 2024 | |||
| 52-Week High Price (Date) | Aug 30, 2023 | |||
| Valuation | GH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.96B | |||
| Enterprise Value | 2.14B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -4.28 | |||
| Earnings Per Share Growth | -33.21% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 3.38 | |||
| Price/Book (Q) | 12.32 | |||
| Enterprise Value/Revenue (TTM) | 4.03 | |||
| Price | $16.67 | |||
| Enterprise Value/EBITDA (TTM) | -5.20 | |||
| Enterprise Value/EBIT | -4.74 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | GH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 118.51M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | GH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 855 698 8887 | |||
| Address | 3100 Hanover Street Palo Alto, CA 94304 | |||
| Website | guardanthealth.com | |||
| Country | United States | |||
| Year Founded | 2011 | |||
| Profitability | GH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -85.07% | |||
| Profit Margin | -85.01% | |||
| Management Effectiveness | GH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -17.66% | |||
| Return on Equity | -- | |||
| Income Statement | GH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 563.95M | |||
| Total Revenue (TTM) | 563.95M | |||
| Revenue Per Share | $4.76 | |||
| Gross Profit (TTM) | 336.90M | |||
| EBITDA (TTM) | -436.87M | |||
| EBIT (TTM) | -479.76M | |||
| Net Income (TTM) | -479.45M | |||
| Net Income Avl. to Common (TTM) | -479.45M | |||
| Total Revenue Growth (Q YOY) | 22.19% | |||
| Earnings Growth (Q YOY) | -33.67% | |||
| EPS Diluted (TTM) | -4.28 | |||
| EPS Diluted Growth (Q YOY) | -15.63% | |||
| Balance Sheet | GH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.17B | |||
| Cash Per Share (Q) | $9.86 | |||
| Total Current Assets (Q) | 1.35B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 158.68M | |||
| Current Ratio (Q) | 6.542 | |||
| Book Value Per Share (Q) | $1.30 | |||
| Total Assets (Q) | 1.79B | |||
| Total Current Liabilities (Q) | 205.92M | |||
| Total Debt (Q) | 1.35B | |||
| Total Liabilities (Q) | 1.63B | |||
| Total Common Equity (Q) | 158.68M | |||
| Cash Flow | GH - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 840.25M | |||
| Cash from Financing (TTM) | 477.38M | |||
| Net Change in Cash (TTM) | 991.74M | |||
| Levered Free Cash Flow (TTM) | -177.69M | |||
| Cash from Operations (TTM) | -324.98M | |||
